Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more New White House drug pricing deals might not amount to much, at least not immediately

https://www.statnews.com/pharmalot/2026/09/02/uniqure-huntingtons-fda-novo-nordisk-investors-pharmalittle-newsletter/ By Andrew JosephSept. 2, 2026 Europe Correspondent